最新报道：According to Bijie.com, on September 16th, the share price of Yaojie Ankang, an innovative pharmaceutical company listed on the Hong Kong Stock Exchange, soared over 60% during intraday trading, bringing its market capitalization to nearly HK$270 billion. Since its listing on June 23rd, its share price has skyrocketed over 50-fold in less than three months, earning it the nickname "Hong Kong's version of the Meme Coin," becoming a new hotspot for speculation amidst the frenzy of capital. Yaojie Ankang's surge was triggered by the implicit clinical approval of a clinical trial for its core product, Engotinib. Hailed as "the world's first FGFR inhibitor to enter registration-stage clinical trials," the drug holds enormous market potential. However, the company has no commercialized products, has accumulated losses of 870 million yuan over three years, and will have no revenue until the first half of 2025. Its "hundred-billion-yuan market capitalization" is more like a meme coin in the crypto market, driven by narratives and lacking fundamental support. BiyaPay analysts point out that Yaojie Ankang's performance is similar to familiar meme coins in the cryptocurrency world: a small circulating stock, strong news incentives, and an influx of capital driven by sentiment. Driven by capital, stock prices have surged rapidly in the short term, but whether they can maintain long-term stability remains uncertain. For crypto investors, this "new meme coin" trend in Hong Kong stocks is becoming a new speculative battlefield. Through BiyaPay, users can not only trade digital currencies like BTC and ETH with zero fees, but also participate in US and Hong Kong stock investments in one place, seize opportunities in "monster stocks" like Yaojie Ankang, and achieve flexible cross-market allocation.